Novo Nordisk licenses kidney disease drug from Epigen

Novo Nordisk has picked up the worldwide rights to a kidney disease drug in development at Epigen. The agreement gives Novo control of orally available LPA1 receptor antagonist EPGN696 in exchange for up to $200 million in upfront and milestone payments.